Background The role of endothelin-1 (ET-1) and nitric oxide (NO) as two important mediators in the development of cerebral vasospasm (CVS) after subarachnoid haemorrhage (SAH) is controversial. The objective of this study was to determine whether local levels of ET-1 and NO in cerebral arterial plasma and/or in cerebrospinal fluid (CSF) are associated with the occurrence of CVS after SAH. Methods CVS was induced using the one-haemorrhage rabbit model and confirmed by digital subtraction angiography of the rabbits' basilar artery on day 5. Prior to sacrifice, local CSF and basilar arterial plasma samples were obtained by a transclival approach to the basilar artery. Systemic arterial plasma samples were obtained. ET-1 levels were determined by immunometric technique (pg/ml ± SEM) and total nitrate/nitrite level spectrophotometrically (µmol/l ± SEM). Findings Angiographic CVS was documented after SAH induction (n=12, P<0.05). The ET-1 level in CSF was significantly elevated by 27.3% to 0.84±0.08 pg/ml in SAH animals (n=7) in comparison to controls (0.66±0.04 pg/ml, n=7, P<0.05). There was no significant difference in ET-1 levels in systemic and basilar arterial plasma samples of SAH animals compared to controls. A significant lack of local NO metabolites was documented in basilar arterial plasma after SAH (36.8±3.1 µmol/l, n=6) compared to controls (61.8±6.2 µmol/l, n=6, P<0.01). Conclusion This study demonstrates that an elevated ET-1 level in CSF and local lack of NO in the basilar arterial plasma samples are associated with CVS after experimental SAH.
ischaemia, permanent neurological dysfunction and death [21] . Despite substantial progress in the understanding of the development of CVS after SAH, its pathogenesis remains unclear with regard to its complexity. In addition to haemolytic metabolites recently discovered to be pathogenetic factors, such as oxyhaemoglobin and bilirubin oxidation products [4] , the probably most important factors contributing to the narrowing of cerebral arteries after SAH are dysfunctions observed in the endothelin-1 (ET-1) and nitric oxide (NO) system as a result of haemolytic processes in the subarachnoid space [21] .
ET-1 is the most potent vasoconstrictive endogenous peptide produced by various cells, including endothelial cells, smooth muscle cells, astrocytes and neurons [13] . In both experimental and clinical studies, elevated levels of ET-1 in either cerebrospinal fluid (CSF) and/or peripheral plasma have been observed to be associated with the occurrence of CVS [9, 12, 35] ; however, none of the studies has focused on the local cerebral plasma levels as the bridge between CSF and the periphery. The therapeutic approach in affecting the system by selective endothelin A receptor antagonism seems to be promising according to preliminary clinical results [3, 31] . However, ET-1's source and cause of release remain unclear. Some researchers propose that ET-1 is induced by cerebral ischaemia and released from astrocytes, leading to elevated levels in CSF [12, 22] . Others propose that elevated ET-1 levels observed in peripheral plasma samples are directly associated with CVS as a result of endothelial dysfunction [9, 10] .
Nitric oxide synthase mediates oxygen-dependent conversion from l-arginine to radical NO, leading to vasodilation through the cyclic guanylate monophosphate pathway [2] . Decreased bioavailability of endogenous NO has been widely accepted as an important part of the pathogenesis of delayed CVS after SAH, more likely caused by decreased production than by increased scavenging by haemolytic metabolites as was initially assumed [21] . Controversies about the origin of decreased availability remain because of conflicting data published about NO metabolite levels in the CSF and peripheral plasma [8, 21, 25] .
On the basis of a novel sampling approach, our study seeks to include local cerebral plasma levels as a further variable to focus on for bridging a gap between conflicting data published about CSF and peripheral plasma levels of ET-1 and NO. With the use of an experimental SAH model, it compares local basilar arterial plasma levels of ET-1 and NO metabolites with those in CSF as well as compares them to systemic arterial plasma levels. This may possibly contribute to the clarification of conflicting data published on the source of release of ET-1 and reduced bioavailability of NO.
Methods and materials

In vivo
The protocol of this study was reviewed and approved by the Swiss Institutional Animal Care and Use Committee and meets the Swiss guidelines for laboratory animal use (Canton Bern, Switzerland, approval no. 15/06).
Experimental groups
A total of 24 adult New Zealand white rabbits of either sex weighing 2.6 to 3.6 kg were randomly assigned to two groups (12 animals each). One group underwent experimental SAH on day 0, and one served sham-operated as control.
Angiography
After induction of general anaesthesia by intramuscular administration of ketamine (30 mg/kg) and xylazine (6 mg/kg), digital subtraction angiograms (DSA) were performed on day 0 prior to SAH and on day 5 post SAH. The rabbits' left (day 0) or right (day 5) subclavian artery was microsurgically cannulated using a 0.5-mm plastic tube. The catheter was fixed distal to the vertebral branch. Subsequently, DSA was performed by intraarterial bolus injection of non-ionic iopamidol (0.6 ml/kg) as contrast agent. Meanwhile, the arterial blood gas status was analysed to monitor ventilation parameters from a collected arterial blood sample. Images of the vertebrobasilar system were obtained using a rapid sequential angiographic technique with the small focal spot at 66 kV 125 mA (DFP 2000A, Toshiba Corporation®, Japan). The average diameter of the basilar artery was digitally calculated in μm using the automatic measurement tool of ImagePro Discovery® analysis software (MediaCybernetics, Bethesda, MD).
Cerebral vasospasm model
Following baseline DSA on day 0, the rabbits' atlantooccipital membrane was exposed by a microsurgical posterior approach in prone position, and a 25-gauge needle was inserted into the cerebromedullar cistern while maintaining general anaesthesia. After relief of 1.0 ml CSF, an equal amount of unheparinised autologous arterial blood in the SAH group was injected into the cistern under microscopic view to imitate SAH in order to induce CVS. An equal amount of isotonic saline solution instead was injected in controls. Postsurgical pain relief was managed by subcutaneous administration of buprenorphine (0.1-0.2 mg/kg).
Collection of samples
Following post-treatment DSA on day 5, the rabbits underwent coniotomy to keep up general anaesthesia by inhalation of an isoflurane/oxygen/air mixture (2.5/5/ 92.5 vol%). Systemic arterial plasma samples were collected via the central arterial catheter. Basilar arterial plasma and CSF samples were collected by a transclival approach. In brief, the rabbits' head was reclined and fixed at a 20°angle, the trachea and oesophagus were cautiously laterally retracted and the musculature underneath bluntly microsurgically dissected. The paravertebral venous plexus exposed in the depth was coagulated using a pair of bipolar forceps. The exposed dorsocaudal edge of the clivus was followed frontocranially by cautious dissection until the clivus' surface on the base of the skull could fully be displayed. A compression of the carotid arteries and the descending vagus nerves was avoided throughout the procedure.
An ellipsoid osteotomy (2-mm diameter) with the use of a high-speed microdrill (Fine Science Tools, North Vancouver, BC, Canada) exposed the dura and the basilar artery underneath. The CSF sample was collected by transdural insertion of a 26-gauge bent needle into the subarachnoid space. The part of the dura exposed was fully excised with microscissors in order to allow a direct approach to the distal segment of the basilar artery. The basilar arterial blood sample was collected by intraluminal insertion of a 29-gauge bent needle into the basilar artery. The collected blood samples were centrifuged for 15 min at 1,500 rpm, and the plasma remnants and CSF samples were stored at -80°C. The animals were killed by intraarterial bolus injection of sodium thiopenthal (40 mg/kg). All surgical procedures were performed under sterile conditions.
In vitro
Detection of ET-1
In seven randomly chosen animals of each group, ET-1 systemic and basilar plasma levels as well as CSF levels were quantitatively determined by the extraction-free human ET-1 chemiluminescent sandwich immunoassay technique (QuantiGlo QET00B, R&D Systems, Minneapolis, MN) as previously validated [18] . The amino acid sequence of human ET-1 matches rabbit ET-1 exactly. The quantitative range of the assay is 0.32 to 1,000 pg/ml. According to the manufacturer, crossreactions of antibodies used are observed for human ET-1 (100%), human big ET-2 (0.01%), human big ET-38 (0.019%), human ET-3 (7.8%) and human ET-2 (27.4%).
Measurement of NO metabolites
In six random animals of each group, nitrite/nitrate levels were quantitatively determined as a relative measure for basilar, systemic plasma and CSF levels of NO production, as is common practice. Following reduction of nitrate to nitrite with a modified Griess method, the total nitrite level was spectrophotometrically detected at 540 nm (QuantiChrom Nitric Oxide Assay Kit, Bioassay Systems, Hayward, CA) as previously validated [24] .
Drugs
The following drugs were used: buprenorphinum (Temgesic® 0.3 mg/ml, Essex Chemie, Lucerne, Switzerland), iopamidol (Iopamiro® 300 mg/ml, Bracco, Milan, Italy), isoflurane (Forene® 99%, Abbott Laboratories, Abbott Park, IL), ketamine HCl (Ketalar®50 mg/ml, Pfizer AG, Zurich, Switzerland), sodium thiopenthalum (Pentothal® 25 mg/ml, Abbott Laboratories, Abbott Park, IL) and xylazine HCl (Xylapan® 20 mg/ml, Vetoquinol AG, Bern, Switzerland).
Statistical methods
Values are expressed as mean ± SEM (n=number of animals). Statistical difference between two means and multiple means was determined by Student's unpaired t-test and one-way ANOVA followed by Bonferroni's posttesting, respectively. The statistical significance was considered if the P-value was less than 0.05 (p<0.05) in context of the 95% confidence intervals of the difference examined (95% CI of diff).
Results
Arteriographic vasospasm
On day 5 after SAH, the diameter of the basilar artery was significantly narrowed by 11.7% to 692.2 ± 23.0 µm (n= 12) compared to the animals' baseline angiogram on day 0 (783.5 ± 25.1 µm, n=12, P<0.01, 95% CI of diff: 15.4 to 167.2 µm); on the same day, the basilar artery diameter remained unchanged (778.5 ± 25.8 µm, n=12) in the control group compared to the baseline on day 0 (787.2 ± 17.8 µm, n=12, P>0.05, 95% CI of diff: -84.6 to 67.2 µm) (Fig. 1) .
The animals' initial blood pressure at baseline angiography (SAH group: 71.1 ± 2.8 mmHg in mean arterial pressure, n=12; controls: 68.8 ± 2.0 mmHg, n=12) was not different from the values monitored on day 5 in both the SAH group (70.6 ± 2.2 mmHg, n=12, P>0.05) and the controls (70.8 ± 2.1 mmHg, n=12, P>0.05). Correspond-ingly, the initial blood gas parameters such as pO 2 (SAH group: 57.9 ± 3.6 mmHg; controls: 56.8 ± 2.1 mmHg), pCO 2 (SAH group: 50.6 ± 1.1 mmHg; controls: 50.1 ± 1.3 mmHg) and pH (SAH: 7.39 ± 0.01; controls: 7.38 ± 0.01) did not change compared to the values monitored during follow-up angiography on day 5 in both the SAH (P>0.05) and control group (P>0.05) and did not statistically differ between the two groups (P>0.05).
Local ET-1 levels
The ET-1 level in CSF samples was significantly elevated by 27.3% to 0.84 ± 0.08 pg/ml in SAH animals (n=7) in comparison to controls (0.66 ± 0.04 pg/ml, n=7, P<0.05, 95% CI of diff: 0.01 to .35 pg/ml). There was a slight increasing tendency observed in plasma samples as well, but no significant difference of ET-1 levels was remarked in systemic or basilar arterial plasma samples of SAH animals compared to controls. Local levels of ET-1 in the basilar arterial plasma samples did not statistically differ from those in the systemic plasma in SAH (n=7, P≥ 0.05, 95% CI of diff: -0.12 to 0.53 pg/ml) or control groups (n=7, P≥0.05, 95% CI of diff: -0.05 to 0.44 pg/ml), nor did they statistically differ from those in CSF of the SAH (P≥0.05, 95% CI of diff: -0.51 to 0.10 pg/ml) or control groups (P ≥ 0.05, 95% CI of diff: -0.51 to 0.09 pg/ml) (Fig. 2) .
Local levels of NO metabolites
The level of total nitrate/nitrite in the basilar arterial plasma samples was significantly reduced, by 40.4% to 36.8 ± 3.1 µmol/l in SAH animals (n=6) compared to controls (61.8 ± 6.2 µmol/L, n=6, P<0.01, 95% CI of diff: 9.5 to 40.3 µmol/l). A slightly decreasing tendency of the local NO metabolite level was also observed in CSF (n=6) and systemic arterial plasma (n=6) samples in comparison to the controls (n = 6), but remained insignificant (P>0.05). The local level of total nitrate/ nitrite in basilar arterial plasma samples did not differ statistically from the level in systemic samples for both the SAH group (n=6, P>0.05) and the control group (n= 6, P>0.05). It was significantly higher than the level detected in CSF samples for both the SAH group (n=6, P<0.001, 95% CI of diff: 15.9 to 37.1 µmol/l) and the control group (n=6, P<0.001, 95% CI of diff: 28.5 to 62.7 µmol/l) (Fig. 3) . 
Discussion
Origin of increased bioavailability of ET-1 ET-1 is produced by various cells, including neurons, glial cells, smooth muscle cells and endothelial cells, within minutes after being stimulated by hypoxia, ischaemia and shear stress [13] . Its release from vascular endothelial and smooth muscle cells is more likely to follow a paracrine than an endocrine pattern, as ET-1 abluminally binds to ETA receptors in the smooth muscle cell layer to mediate long-lasting vasoconstriction [13, 32] . Despite broad acceptance of ET-1 as a contributing mediator of CVS, conflicting data have been reported about the correlation of ET-1's plasma level and CVS. On one hand, ET-1's peripheral plasma level has been found to correlate with the severity of vascular diseases [13] , as shown in clinical studies of Juvela et al. [9, 10] and Suzuki et al. [30] in regard to the occurrence of delayed cerebral ischaemia and vasospasm after SAH. On the contrary, other authors were not able to correlate ET-1 plasma levels to CVS [11, 12, 27] .
In our experimental study neither the local ET-1 level in the basilar arterial nor the one in systemic plasma samples after SAH differed significantly from those in controls. These findings support the clinical observations reported elsewhere [11, 12, 27] . In addition, our data did not show significant differences between the local ET-1 level obtained from basilar arterial plasma samples compared to the systemic samples within either the SAH or the control group. Nevertheless, our results demonstrated a trend towards lower levels of this peptide in the basilar arterial samples than in the peripheral plasma in both groups. This observation might suggest that the elevated peripheral plasma levels of ET-1 observed in clinical studies are rather unlikely to be caused by increased release of ET-1 into the cerebral circulation [9, 10, 30] . One reason might be that the systemic plasma ET-1 concentration could be significantly influenced by physiological and pathological conditions in structures other than the brain and cerebral vessels, as shown, for example, in systemic hypertension and heart failure [13, 35] .
Instead, our data demonstrated a significantly elevated ET-1 level in CSF on day 5 after experimental SAH. This observation supports the hypothesis of mediated CVS partly due to elevated ET-1 levels in CSF. In experimental studies on felines and canines, intracisternal bolus injections of ET-1 have previously demonstrated ET-1's potency in mediating vasoconstriction from the abluminal site [16] . Pluta et al.'s experimental study in primates found the ET-1 level in CSF to be dependent on astrocyte release [22] . Our finding of an elevated level of ET-1 in CSF confirms the clinical results reported earlier [11, 12, 14, 27, 28] . Among these reports the correlation of the CSF to the plasma levels of ET-1 in SAH-induced CVS is still controversial. With respect to the apparently very limited specificity and sensitivity of ET-1 in systemic plasma to correlate with CVS, some authors showed ET-1's peripheral plasma concentration during CVS to act differently from the one in CSF [12, 27] , while Kastner et al. demonstrated them to be relatively similar in concentration averaged over time [11] . Keeping in mind that ET-1 levels of local cerebral plasma and CSF had not been previously examined, we documented the basilar arterial plasma levels of ET-1 to be statistically indifferent from the ones in CSF. These findings might possibly be explained epiphenomenally due to the ET-1 conversion rate in the endothelial basilar arterial layer or due to ET-1 release from the CSF into the cerebral circulation. This hypothesis might also be supported by Menon et al. who found high arteriojugularvenous ET-1 gradients in patients suffering from SAH-induced CVS [15] .
Though our study results tend to agree with these hypotheses, one needs to keep in mind that the SAH model used in this study is certainly limited in mimicking the complex clinical conditions of an aneurysmal SAH in humans. Due to single time point assessment during the peak time of CVS, the study is also limited in providing data about possible metabolite level changes during the development of CVS.
Origin of reduced NO bioavailability
Endogenous NO is a radical product of the oxidation of l-arginine to citrulline by nitric oxide synthase, which causes vasodilation through activation of the soluble guanylate cyclase pathway. Three isoenzyme forms are known to play a role in vasculature-mediating NO release: induced nitric oxide synthase (iNOS), periadventitial neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS). While iNOS possibly plays a pathophysiological role in the acute and early states after SAH, there is debate over whether the activity of nNOS and eNOS has a role in the delayed development of CVS after SAH [5, 21] . After a short half-life, radical NO is metabolised by being oxidised to stable nitrite and nitrate. This serves as an acceptable relative measure of NO level in both experimental and clinical research. Decreased bioavailability of NO has been shown to be associated with the development of delayed CVS after SAH, more likely caused by deprived production rather than just increased scavenging by haemolytic metabolites such as oxyhaemoglobin as initially assumed [5, 21] .
This study demonstrated the novel finding that locally reduced NO availability in basilar arterial plasma is associated with CVS after SAH. It hypothesises that there is decreased production of NO in the endothelial layer of local cerebral vasculature. This local lack of NO in the basilar plasma might hypothetically be explained by dysfunctional endothelium [7] or by inhibited enzyme activity of eNOS [8] . Whether these results are caused by downregulation of eNOS expression itsself, however, remains uncertain because of the conflicting data reported: Hino et al. [6] found decreased eNOS mRNA in cerebral arteries of primates and Park et al. [20] in the microvasculature of rats after induced SAH. On the contrary, Vatter et al. could recently not reproduce those findings by histochemical staining of eNOS in the rats' basilar artery after SAH [33] . In support of our hypothesis, Jung et al. found that the level of asymmetric dimethylarginine, an endogenous competitive inhibitor of nitric oxide synthase and a metabolisation product of bilirubin, was elevated in CSF during delayed CVS in an experimental primate model [8] . It is suggested to contribute to the endogenous inhibition of eNOS [8] and, thus, possibly to the lack of NO in the basilar arterial plasma found in our study.
Uncertainty remains about conflicting data reported for NO metabolites after SAH concerning the CSF level. While some authors reported in clinical studies with small sample sizes that NO metabolite levels in CSF were increased after SAH [17, 25, 29, 34] ; others observed CVS to be associated with reduced CSF levels of nitrite [26] , suggesting possible affection of nNOS [8, 23] . However, our data do not confirm any significant change in nitrite level in CSF in either direction. Possible explanations for the conflicting data published are a lack of large clinical sample sizes, different time courses, and different spots of vessel catheterisation and sample collection.
Our data also do not demonstrate a significant difference between nitrite levels in systemic plasma after SAH compared to controls, in agreement with clinical data provided by Suzuki et al. [29] . It suggests that systemic plasma may be too unspecific to detect a locally limited pathophysiological process in the cerebrovascular NO system.
Interaction of ET-1 and NO
Experimental data have been published suggesting that there may be a direct or indirect interaction between the ET-1 and NO systems on the basis of a yet unclear mechanism. Ohkita et al. provided evidence for inhibition of ET-1 production by NO, assuming a modulatory role of NO [19] . Impairment of this possible modulatory role of NO on ET-1 during CVS after SAH has been found by Alabadi et al. [1] and supports our observation that an elevated ET-1 level in CSF accompanies a lack of local NO.
(EDRF), [3] that endothelin-1 (ET-1), a venom from the sarafotoxin family, is produced in our bodies by endothelial cells as the most potent vasoconstrictor [4] and that both regulate cerebral blood have given new hope to develop a cure for vasospasm.
In the 1990s, numerous studies suggested that NO or ET-1 was involved in the development of delayed cerebral vasospasm, [5, 6] while other reports denied such a relationship. [7, 8] The controversy is still ongoing although preclinical and clinical trials using intracarotid infusion of NO gas solution, [9] intracarotid or intrathecal administration of NO donors [10] [11] [12] and ET-1 receptor inhibitors have claimed clinical success. [13, 14] However, better understanding of aSAH pathophysiology, discovery of new aSAHrelated events like cortical spreading ischemia [15] and, probably most importantly, the failure of Clazosentan, a selective ET-1 A receptor inhibitor, in Phase II clinical study [2] to improve the outcome despite prevention of vasospasm all lead to a paradigm shift with the focus on the possibility that a stroke after aSAH may be evoked by another nonvasospasm-related mechanism(s). Growing body of evidence suggests that these pathomechanisms are a result of the presence of an arterial blood clot in the subarachnoid space, increased ET-1 in CSF, and decreased availability of NO in cerebral arteries. [2, 15] In their clever, well-planned and executed, but most confirmatory in vivo experimental study published in this issue of Acta Neurochirugica , V. Neuschmelting and colleagues simultaneously examined the role of both NO and ET-1 in the development of vasospasm in a rabbit model of aSAH. To assure the relevance of their findings, the authors used an innovative surgical approach. They collected blood samples directly from the basilar artery to compare to the peripheral arterial blood and CSF samples. The authors convincingly showed that the presence of ET-1 in the CSF and endothelial NOS dysfunction were associated with vasospasm development. These findings, while not altogether new, [6, 10, 11, 13, 14] are a novel approach to sample collection and shed new light on the pathophysiology of vasospasm after SAH by separating the extra-and intravascular events. Doing this further opens the door to a Kuhnian revolution in our understanding the role of vasospasm in stroke after aSAH and hopefully leads to successful treatment of this dreadful complication of a ruptured intracranial aneurysm.
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